Merck KGaA Turns To Outsider Oschmann To Head Pharma Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck & Co.'s emerging markets head Stefan Oschmann will succeed Merck KGaA's Elmar Schnee as head of pharmaceuticals effective Jan. 1.
You may also be interested in...
Merck Serono/Dr. Reddy's Biosimilars Deal Includes Co-Commercialization In U.S.
In most of the world, Germany's Merck Serono will have exclusive rights and India’s Dr. Reddy's will receive royalties on the oncology biosimilars which will be developed as part of the collaboration; but in the U.S. and select emerging markets, the Indian company retains co-commercialization rights.
Merck Serono/Dr. Reddy's Biosimilars Deal Includes Co-Commercialization In U.S.
In most of the world, Germany's Merck Serono will have exclusive rights and India’s Dr. Reddy's will receive royalties on the oncology biosimilars which will be developed as part of the collaboration; but in the U.S. and select emerging markets, the Indian company retains co-commercialization rights.
Merck KGaA 2010 Results Marred By Cladribine And Poor OTC Growth
Millipore acquisition boosts 2010 results for Germany's Merck, but pharma strategy remains unclear.